SMS Pharmaceuticals Share Price Today (SMSPHARMA)
TODAY IN ONE LINE
SMSPHARMA fell 2.9% on light volume, lagging Nifty's -0.0% move.
With a market cap of ₹3,560.18 Cr., it trades at a P/E of 34.95. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SMS Pharmaceuticals flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 49.2% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 19.3%
- ●High Promoter HoldingPromoters hold 68.1% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Promoter BuyingPromoters increased holdings by 1.80% QoQ
Red Flags
- ●Sales ContractionQuarterly sales dropped 4.1% YoY
- ●Promoter Pledging DetectedPledge activity recorded on 23-Aug-2025 17:32
Latest SMS Pharmaceuticals News
What changed recently?
Recent events, corporate actions, and announcements.
SMS Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SMS Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
SMS Pharmaceuticals Limited trades at a P/E of 34.95× and P/B of 4.54×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SMS Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for SMS Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
SMS Pharmaceuticals Limited last traded at ₹380.75 with an intraday range of ₹379.3–₹391.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹380.75| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 413.87 | +33.12 | +8.70% |
| R3 | 401.27 | +20.52 | +5.39% |
| R2 | 396.58 | +15.83 | +4.16% |
| R1 | 388.67 | +7.92 | +2.08% |
| PIVOT | 383.98 | 3.23 | 0.85% |
| CURRENT | 380.75 | — | — |
| S1 | 376.07 | -4.68 | -1.23% |
| S2 | 371.38 | -9.37 | -2.46% |
| S3 | 363.47 | -17.28 | -4.54% |
| S4 | 350.87 | -29.88 | -7.85% |
SMSPHARMA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹386.05–₹391.9
Trading Below opening range, showing Bearishness
SMS Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SMS Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
SMS Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,560.18 Cr. and reported EPS of ₹11.17.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 783 | 887 ▲ 13.3% |
| Sales Growth YoY %Derived | 10.36% | 13.30% |
| Other Income | 6 | 8 ▲ 34.2% |
| Total Income | 789 | 895 ▲ 13.5% |
| 437 | 493 ▲ 12.9% | |
| Gross ProfitDerived | 346 | 394 ▲ 13.8% |
| Gross Margin %Derived | 44.16% | 44.37% |
| 207 | 222 ▲ 7.5% | |
| EBITDA (Operating Profit)Derived | 139 | 171 ▲ 23.2% |
| OPM %Derived | 17.76% | 19.31% |
| 53 | 63 ▲ 19.1% | |
| Profit Before Tax (PBT) | 92 | 117 ▲ 26.3% |
| 25 | 29 ▲ 14.8% | |
| Effective Tax %Derived | 27.01% | 24.55% |
| Total Profit for Period | 69 | 102 ▲ 47.5% |
| Net Profit (Owner's PAT)Derived | 69 | 102 ▲ 47.5% |
| Net Profit Margin %Derived | 8.83% | 11.50% |
| PAT Growth YoY %Derived | 38.75% | 47.52% |
| Earnings Per Share (EPS ₹) | 7.80 | 10.90 ▲ 39.7% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 5.6% |
| Share of Profit from Associates/JVs | 2 | 14 ▲ 705.6% |
| Other Comprehensive Income (Net of Tax) | -1 | 0 ▲ 119.2% |
| Total Expenses (incl. D&A & Interest) | 697 | 779 ▲ 11.8% |
| Material Cost % of RevenueDerived | 64.12% | 58.23% |
| Employee Cost % of RevenueDerived | 10.23% | 9.92% |
| Other Cost % of RevenueDerived | 16.18% | 15.14% |
| Interest Coverage (x)Derived | 5.64x | 5.69x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 465 | 412 ▼ 11.4% | 563 ▲ 36.7% | 520 ▼ 7.7% | 522 ▲ 0.4% | 709 ▲ 35.9% | 783 ▲ 10.4% | 887 ▲ 13.3% | |
| Sales Growth YoY %Derived | — | -11.39% | 36.71% | -7.69% | 0.42% | 35.86% | 10.36% | 13.30% | |
| Other Income | 3 | 5 ▲ 50.3% | 3 ▼ 32.5% | 5 ▲ 50.5% | 5 ▼ 6.0% | 4 ▼ 8.7% | 6 ▲ 39.6% | 8 ▲ 34.2% | |
| Total Income | 468 | 417 ▼ 10.9% | 567 ▲ 35.9% | 525 ▼ 7.3% | 527 ▲ 0.4% | 714 ▲ 35.4% | 789 ▲ 10.5% | 895 ▲ 13.5% | |
293 | 246 ▼ 15.8% | 340 ▲ 38.0% | 275 ▼ 19.0% | 336 ▲ 21.9% | 424 ▲ 26.3% | 437 ▲ 3.0% | 493 ▲ 12.9% | ||
| Gross ProfitDerived | 172 | 166 ▼ 3.8% | 223 ▲ 34.8% | 244 ▲ 9.5% | 186 ▼ 23.8% | 285 ▲ 53.0% | 346 ▲ 21.3% | 394 ▲ 13.8% | |
| Gross Margin %Derived | 37.04% | 40.20% | 39.63% | 47.02% | 35.67% | 40.18% | 44.16% | 44.37% | |
82 | 86 ▲ 4.3% | 102 ▲ 19.1% | 130 ▲ 27.5% | 132 ▲ 1.3% | 168 ▲ 27.8% | 207 ▲ 22.8% | 222 ▲ 7.5% | ||
| EBITDA (Operating Profit)Derived | 90 | 80 ▼ 11.3% | 121 ▲ 51.5% | 114 ▼ 5.6% | 55 ▼ 52.3% | 117 ▲ 114.0% | 139 ▲ 19.2% | 171 ▲ 23.2% | |
| OPM %Derived | 19.38% | 19.40% | 21.50% | 21.99% | 10.44% | 16.44% | 17.76% | 19.31% | |
31 | 34 ▲ 10.1% | 33 ▼ 2.4% | 51 ▲ 52.6% | 54 ▲ 5.9% | 55 ▲ 1.7% | 53 ▼ 3.8% | 63 ▲ 19.1% | ||
| Profit Before Tax (PBT) | 62 | 51 ▼ 18.6% | 91 ▲ 79.5% | 68 ▼ 24.8% | 5 ▼ 92.2% | 66 ▲ 1135.8% | 92 ▲ 39.7% | 117 ▲ 26.3% | |
9 | 18 ▲ 102.9% | 30 ▲ 66.9% | 1 ▼ 97.9% | 1 ▲ 137.0% | 17 ▲ 1054.0% | 25 ▲ 47.5% | 29 ▲ 14.8% | ||
| Effective Tax %Derived | 14.28% | 35.60% | 33.09% | 0.90% | 27.39% | 25.57% | 27.01% | 24.55% | |
| Total Profit for Period | 53 | 33 ▼ 38.8% | 63 ▲ 91.3% | 62 ▼ 0.5% | -7 ▼ 111.3% | 50 ▲ 805.8% | 69 ▲ 38.8% | 102 ▲ 47.5% | |
| Net Profit (Owner's PAT)Derived | 53 | 33 ▼ 38.8% | 63 ▲ 91.3% | 62 ▼ 0.5% | -7 ▼ 111.3% | 50 ▲ 805.8% | 69 ▲ 38.8% | 102 ▲ 47.5% | |
| Net Profit Margin %Derived | 11.50% | 7.94% | 11.10% | 11.97% | -1.35% | 7.03% | 8.83% | 11.50% | |
| PAT Growth YoY %Derived | — | -38.84% | 91.28% | -0.49% | -111.35% | 805.82% | 38.75% | 47.52% | |
| Earnings Per Share (EPS ₹) | 6.31 | 3.86 ▼ 38.8% | 7.39 ▲ 91.5% | 7.35 ▼ 0.5% | -0.83 ▼ 111.3% | 5.89 ▲ 809.6% | 7.80 ▲ 32.4% | 10.90 ▲ 39.7% | |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 8 ▲ 0.0% | 9 ▲ 4.7% | 9 ▲ 5.6% | |
| Share of Profit from Associates/JVs | — | — | 2 | -6 ▼ 462.4% | -11 ▼ 93.3% | 1 ▲ 105.7% | 2 ▲ 177.4% | 14 ▲ 705.6% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 81.5% | -0 ▼ 253.4% | 0 ▲ 134.2% | -0 ▼ 305.4% | 0 ▲ 141.0% | -1 ▼ 878.2% | 0 ▲ 119.2% | |
| Total Expenses (incl. D&A & Interest) | 406 | 366 ▼ 9.8% | 476 ▲ 29.8% | 457 ▼ 4.0% | 522 ▲ 14.2% | 648 ▲ 24.2% | 697 ▲ 7.6% | 779 ▲ 11.8% | |
| Material Cost % of RevenueDerived | 66.08% | 62.99% | 55.62% | 74.62% | 57.41% | 59.96% | 64.12% | 58.23% | |
| Employee Cost % of RevenueDerived | 7.65% | 9.55% | 7.31% | 9.81% | 10.54% | 9.04% | 10.23% | 9.92% | |
| Other Cost % of RevenueDerived | 10.01% | 11.24% | 10.81% | 15.21% | 14.69% | 14.70% | 16.18% | 15.14% | |
| Interest Coverage (x)Derived | 5.96x | 4.74x | 8.85x | 4.35x | 1.02x | 3.63x | 5.64x | 5.69x |
SMS Pharmaceuticals segment analysis : revenue and profit mix.
Disclosed business segments at SMS Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
SMS Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SMS Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting SMS Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
SMS Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding 68.07% demonstrates strong founder commitment and ownership stability
Latest quarterly EPS grew 61% YoY; TTM EPS grew 49.2% YoY despite valuation concerns
Operating margin 14.81% TTM exceeds CIPLA's 16.2%, signaling superior cost control
Low debt-to-equity ratio 0.0046 indicates conservative leverage and financial prudence
Export network spans 75 countries, providing geographic diversification and global revenue
Key Risks.
P/E 37.66x and EV/EBITDA 33.84x signal premium valuation relative to sector peers
Dividend yield 0.10% offers minimal income appeal for dividend-focused investors
Free cash flow persistently negative; FCF was −₹396.67 Cr in latest quarter
TTM revenue declined 4.1% YoY, indicating underlying demand softness despite quarterly strength
FII ownership collapsed to 0.08% in 2025, signaling foreign investor caution and governance risk
Flip Conditions.
Valuation risk. a P/E above 45 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 9% would indicate weaker capital compounding.
SMS Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SMS Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SMS Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SMS Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
SMS Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SMS Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SMS Pharmaceuticals Limited stood at 64.7% of traded volume, against a 20-day average of 53.8%.
SMS Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings SMS Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SMS Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 126 documents below.
Copy of Newspaper Publication
SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
SMS Pharmaceuticals Limited has informed the Exchange about General Updates
General Updates
SMS Pharmaceuticals Limited has informed the Exchange about General Updates
Certificate under SEBI (Depositories and Participants) Regulations, 2018
SMS Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Spurt in Volume
Significant increase in volume has been observed in SMS Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
General Updates
Investor Presentation
SMS Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SMS Pharmaceuticals has declared, sequenced by announce and record date.
SMS Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
SMS Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in SMS Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
SMS Pharmaceuticals insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| P. Manideep | Insider | 25 Feb 2026 | buy | +2.5 K | ₹10.11 L | ₹404.40 |
| Ramesh Babu Potluri | Insider | 27 Mar 2025 | buy | +25.00 L | ₹23.81 Cr. | ₹95.25 |
| POTLURI INFRA PROJECTS LLP | Insider | 27 Mar 2025 | buy | +15.00 L | ₹14.29 Cr. | ₹95.25 |
| Hima Bindu Potluri | Insider | 25 Mar 2025 | buy | +30.00 L | ₹68.3 Cr. | ₹227.65 |
| POTLURI INFRA PROJECTS LLP | Insider | 25 Mar 2025 | buy | +73.46 L | ₹167.24 Cr. | ₹227.65 |
| Potluri Laboratories Private Limited | Insider | 25 Mar 2025 | buy | +11.20 L | ₹25.5 Cr. | ₹227.65 |
About SMS Pharmaceuticals Limited: business, sector, key facts.
What SMS Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SMS Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SMSPHARMA, BSE: 532815.
SMS Pharmaceuticals Limited is an Indian pharmaceutical company specializing in the manufacturing and sale of active pharmaceutical ingredients (APIs) and their intermediates. Their operations span both domestic and international markets, demonstrating a significant global reach. The company boasts a diverse product portfolio catering to various therapeutic areas, showcasing a wide range of expertise in API development and production.
Their product offerings encompass a broad spectrum of therapeutic applications. This includes crucial medications for treating conditions such as retroviral infections (like HIV/AIDS), inflammation, viral infections, diabetes, fungal infections, epilepsy, migraines, blood clots, psychotic disorders, angina (chest pain), and ulcers. This breadth of therapeutic areas served indicates a commitment to addressing diverse healthcare needs across a substantial patient population.
Beyond their core API manufacturing and sales, SMS Pharmaceuticals also undertakes contract research, specifically focusing on peptide research. This demonstrates an investment in research and development, enabling the company to potentially expand its product offerings and strengthen its technological capabilities within the pharmaceutical sector. The contract research activities might also generate additional revenue streams and allow for collaborations with other research institutions or pharmaceutical companies.
The company's extensive export network, reaching approximately 75 countries globally, underscores its substantial international presence and market penetration. This highlights a successful strategy in establishing and maintaining relationships with international partners and distributors, thereby solidifying their position within the global pharmaceutical landscape. This broad export reach contributes significantly to the company's overall revenue and reinforces its reputation as a prominent player in the international API market.
Established in 1987 and headquartered in Hyderabad, India, SMS Pharmaceuticals has a long history in the pharmaceutical industry. This long-standing presence suggests a proven track record of consistent performance, regulatory compliance, and the establishment of robust operational processes within the competitive pharmaceutical manufacturing sector. Their continued success reflects adaptability to market changes and a strong commitment to meeting the evolving needs of the global healthcare community.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SMS Pharmaceuticals Limited (SMSPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SMS Pharmaceuticals Limited (SMSPHARMA)?
The current share price of SMS Pharmaceuticals Limited (SMSPHARMA) is ₹380.75. Today, the stock has declined by ₹11.15 (2.85%), trading in a range of ₹379.3 to ₹391.9. The stock opened at ₹391.9 with a trading volume of 1,02,761 shares.
02Is SMS Pharmaceuticals Limited stock a good investment for long-term?
SMS Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,560.18 crores, P/E ratio of 34.95, ROE of 14.30%, and ROCE of 13.30%. The dividend yield stands at 0.10%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SMS Pharmaceuticals Limited stock?
The 52-week high price of SMS Pharmaceuticals Limited (SMSPHARMA) is ₹447.8, while the 52-week low is ₹207.99. Currently trading at ₹380.75, the stock is 72.0% away from its 52-week low and 15.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SMS Pharmaceuticals Limited stock at the current price?
Whether to buy SMS Pharmaceuticals Limited stock at ₹380.75 depends on multiple factors. The stock is currently trading with a P/E ratio of 34.95 and P/B ratio of 4.54. Today's performance shows a loss of 2.85%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SMS Pharmaceuticals Limited and when is the next dividend?
SMS Pharmaceuticals Limited offers a dividend yield of 0.10%, which means for every ₹100 invested at the current price of ₹380.75, you can expect to receive approximately ₹0.10 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SMS Pharmaceuticals Limited?
SMS Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 34.95, P/B Ratio: 4.54, ROE: 14.30%, ROCE: 13.30%, Dividend Yield: 0.10%, EPS: ₹11.17, Book Value: ₹81.83, and Debt-to-Equity: 0.46. The company's market cap stands at ₹3,560.18 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SMS Pharmaceuticals Limited stock performing today in the market?
SMS Pharmaceuticals Limited stock opened at ₹391.9 and is currently trading at ₹380.75, showing a decline of ₹11.15 (2.85%). The intraday high is ₹391.9 and low is ₹379.3. The trading volume stands at 1,02,761 shares, indicating moderate market participation today.
08What is the P/E ratio of SMS Pharmaceuticals Limited and what does it indicate?
SMS Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 34.95, which means investors are willing to pay ₹34.95 for every ₹1 of earnings. With an EPS of ₹11.17, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SMS Pharmaceuticals Limited (SMSPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.